The recent free trade agreement (FTA) between India and the European Union marks a significant shift in the pharmaceutical landscape. With the elimination of tariffs on a wide range of pharmaceutical products and medical equipment, this agreement is poised to make novel drugs more accessible to Indian patients while also reducing costs for local manufacturers.
Tariff Reductions and Their Impact
Under the new FTA, tariffs on pharmaceutical exports from Europe to India will drop to zero, down from 11%. This change is expected to substantially improve access to innovative medicines, allowing Indian patients to benefit from advanced treatments that were previously more expensive.
Moreover, the reduction in tariffs will also decrease the input costs for specialized raw materials that Indian pharmaceutical companies import from Europe. This dual benefit is anticipated to enhance the overall efficiency of the Indian pharmaceutical sector.
Expected Financial Implications
Industry insiders predict that the immediate impact of the tariff reductions will be a moderate price drop of approximately 10-20%. However, the real transformation is expected to unfold over the next two to three years, as local manufacturing scales up and the market welcomes biosimilars. Experts forecast that prices could potentially decrease by 40-70% as patent expirations align and production capabilities improve.
This shift holds particular significance for certain therapeutic areas, such as diabetes treatment, where GLP-1 class drugs like semaglutide and tirzepatide are gaining prominence.
Key Import Areas from Europe
India imports a diverse range of pharmaceutical products from Europe, including drugs for oncology, biologics, monoclonal antibodies, insulin analogues, and advanced vaccine technologies such as mRNA and viral vector vaccines. The FTA enhances the flow of these critical therapies into the Indian market, ultimately benefiting public health.
Intellectual Property Protections
While the FTA has been met with enthusiasm, it is worth noting that the Organisation of Pharmaceutical Producers of India (OPPI) is closely examining the detailed provisions of the agreement. Early indications from the European Commission suggest that the FTA will provide robust protections for intellectual property rights. This alignment with both Indian and EU IP laws includes safeguards for trade secrets and undisclosed information, which are vital for fostering innovation.
Opportunities for Domestic Firms
As Europe stands as India’s second-largest pharmaceutical export market, with sales reaching $5.8 billion in the fiscal year 2025, the potential for growth is substantial. Indian pharmaceutical products already enjoy zero duty entry into the EU, but the latest FTA is expected to broaden access, especially for small and medium-sized enterprises (SMEs).
Namit Joshi, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), emphasizes that reduced tariffs and streamlined market entry are crucial for enhancing the ability of SMEs to expand their exports and invest in compliance processes.
Regulatory Challenges and Streamlining
Despite the positive aspects of the FTA, Indian companies still face significant non-tariff barriers in the EU. Approval timelines can extend from two to three years, which hinders timely commercialization. Additionally, registration fees can reach as high as €300,000, posing a material barrier to entry.
The details regarding how the trade deal will affect regulatory processes are still awaited. However, industry experts anticipate that streamlining these processes could yield considerable benefits for Indian exporters.
Medical Equipment Tariff Cuts
In addition to pharmaceuticals, the FTA also addresses medical equipment. Tariffs on European medical equipment exports to India will be reduced to zero from 27.5% for approximately 90% of the products. This dramatic reduction will likely enhance the availability of advanced medical devices in India.
Domestic manufacturers of medical equipment, however, remain cautious. Rajiv Nath, the forum coordinator of the industry body AiMed, has voiced the need for the agreement to ensure a level playing field for Indian medical device manufacturers. He advocates for fair regulatory alignment and protections against potentially predatory imports from other countries.
Conclusion
The India-EU FTA represents a pivotal moment for both pharmaceuticals and medical equipment in India. By eliminating tariffs and facilitating easier access to innovative drugs, the agreement is likely to enhance patient care while providing significant growth opportunities for Indian manufacturers. As the details of the FTA continue to unfold, its long-term impact on the healthcare landscape will become increasingly clear.
- Key Takeaways:
- Tariffs on EU pharmaceuticals to India drop to zero, enhancing access for patients.
- Promising price reductions of 10-20% in the short term, with potential for 40-70% over time.
- Strong focus on intellectual property protections to foster innovation.
- Regulatory streamlining anticipated to benefit Indian exporters.
- Medical equipment tariffs also cut significantly, boosting availability.
Read more → www.livemint.com